APA

Löwenberg B., Beck J., Graux C., van Putten W., Schouten H. C., Verdonck L. F., Ferrant A., Sonneveld P., Jongen-Lavrencic M., von Lilienfeld-Toal M., Biemond B. J., Vellenga E., Breems D., de Muijnck H., Schaafsma R., Verhoef G., Döhner H., Gratwohl A., Pabst T., Ossenkoppele G. J. & Maertens J. (20100503). Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study. : Blood.

Chicago

Löwenberg Bob, Beck Joachim, Graux Carlos, van Putten Wim, Schouten Harry C, Verdonck Leo F, Ferrant Augustin, Sonneveld Pieter, Jongen-Lavrencic Mojca, von Lilienfeld-Toal Marie, Biemond Bart J, Vellenga Edo, Breems Dimitri, de Muijnck Hilde, Schaafsma Ron, Verhoef Gregor, Döhner Hartmut, Gratwohl Alois, Pabst Thomas, Ossenkoppele Gert J and Maertens Johan. 20100503. Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study. : Blood.

Harvard

Löwenberg B., Beck J., Graux C., van Putten W., Schouten H. C., Verdonck L. F., Ferrant A., Sonneveld P., Jongen-Lavrencic M., von Lilienfeld-Toal M., Biemond B. J., Vellenga E., Breems D., de Muijnck H., Schaafsma R., Verhoef G., Döhner H., Gratwohl A., Pabst T., Ossenkoppele G. J. and Maertens J. (20100503). Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study. : Blood.

MLA

Löwenberg Bob, Beck Joachim, Graux Carlos, van Putten Wim, Schouten Harry C, Verdonck Leo F, Ferrant Augustin, Sonneveld Pieter, Jongen-Lavrencic Mojca, von Lilienfeld-Toal Marie, Biemond Bart J, Vellenga Edo, Breems Dimitri, de Muijnck Hilde, Schaafsma Ron, Verhoef Gregor, Döhner Hartmut, Gratwohl Alois, Pabst Thomas, Ossenkoppele Gert J and Maertens Johan. Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study. : Blood. 20100503.